CSPC Pharmaceutical (HKG:1093) obtained approval for a clinical trial of recombinant herpes zoster vaccine from China's National Medical Products Administration.
The indication for the approval is for the prevention of herpes zoster and its complications in adults aged 50 years and above, according to a Thursday filing.